Loncar Cancer Immunotherapy ETF
Limited financial coverage for CNCR.
Not enough data to compute a meaningful composite — typical for foreign-listed ADRs, recent IPOs, or thinly-covered small caps. Live quote, chart, and any available stats still render below.
About the company
This exchange-traded fund tracks an index primarily consisting of common stock from roughly 30 pharmaceutical or biotechnology companies. These firms are handpicked by the index provider due to their strong emphasis on creating innovative drugs that harness the human body's natural immune defenses to combat cancer. The fund's advisor aims to allocate all, or nearly all, of its capital into the underlying securities and American Depositary Receipts (ADRs) that comprise this benchmark index.
- IPO
- 2015
- HQ
- DE, US
Price Chart
- 52W High
- $16.27
- 52W Low
- $7.88
- 50D MA
- $9.18
- 200D MA
- $12.31
- Beta
- 0.96
- Avg Volume
- 2.15K
Get TickerSpark's AI analysis on CNCR
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Our CNCR coverage
Recent articles, reports, and earnings notes.
No research on CNCR yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate CNCR report →Similar companies
Peers in the same neighborhood.